TRAITEMENT DU CANCER ET INHIBITION DES MÉTASTASES UTILISANT UN AGENT ANTI-CELLULES SOUCHES CANCÉREUSES EN COMBINAISON AVEC UN INHIBITEUR DE LA SIALIDASE (NEUL) OU UN INHIBITEUR DE LA CYTOKINE APRÈS UN TRAITEMENT DU CANCER PRIMAIRE
There is provided methods, compositions and treatment regimens for treating cancer, or for inhibiting metastasis/recurrence of cancer in a patient using 1) a primary cancer treatment such as chemotherapy, and 2) within 12 to 120 hours post-primary treatment: a) a first therapeutic agent effective against cancer stem cells, such as a cytotoxic chemotherapy； and b) a second therapeutic agent that disrupts a downstream effect of a tissue repair signalling cascade induced by the primary treatment, including an inhibitor of neu-1 sialidase such as oseltamivir phosphate, or an inhibitor of at least one cytokine associated with stem cell enrichment such as HGF, IL-6, TGF-beta, PGE-2 or PDGF-BB. There is also provided a cancer treatment with chemotherapy agent, such as a checkpoint inhibitor, in combination with either a neuraminidase 1 inhibitor such as oseltamivir phosphate, or a COX-2 inhibitor such as celecoxib, or both.
